Tanja Obradovic: One exciting novel approach is just about to enter clinical development
Tanja Obradovic, Vice President of Oncology Scientific Affairs at
“Cell therapy in the solid tumors has been challenging and numerous next generation options are attempting breakthrough. One exciting novel approach is just about to enter clinical development. MDG1015, a first-in-class, third generation T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1/ LAGE-1a (New York oesophageal squamous cell carcinoma 1 / L Antigen Family Member-1a), armored and enhanced with the PD1-41BB co-stimulatory switch protein (CSP) made by very innovative team at Medigene AG. PhI trail is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024. More on MDG1015 is just about to be presented at Immuno-Oncology Summit Europe in few days.”
Source: Tanja Obradovic/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.